Comments
Exclusive: Questionable data propped up cancer drug Provenge
12.10.2012. | NEW YORK (Reuters) - In Dendreon Corp's most important clinical trial for the controversial cancer therapy Provenge, researchers analyzed some of the data differently from how the company told U.S. regulators they would, according to documents reviewed by Reuters....
